• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Jupiter Endovascular Exits Stealth With $21M in New Financing to Fund Pivotal Trial for Pulmonary Embolism

    8/15/24 10:00:00 AM ET
    $ISRG
    $PRCT
    Industrial Specialties
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ISRG alert in real time by email

    Carl J. St. Bernard Appointed as Chief Executive Officer

    Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal ControlTM to bring the precision and control of direct surgical access to catheter-based interventions, announced today that it has exited stealth mode with a $21 million new round of financing. Sonder Capital was a key participant in the round that included participation from multiple strategic investors. The funding will be used to support the company's upcoming pivotal trial for Pulmonary Embolism and development of additional clinical applications of the Endoportal ControlTM technology.

    "For decades, the field of catheter-based therapies has been limited by the technological constraints of catheters that lose stability and control within the anatomy," said Kate Garrett, Managing Partner at Sonder Capital. "Jupiter Endovascular has developed a revolutionary approach with the potential to overcome these constraints by providing clinicians the precision and control of a surgical approach while maintaining the minimally invasive profile of an endovascular procedure. This novel approach may address a significant unmet clinical need in patients with disease residing in complex cardiovascular anatomies, such as the pulmonary arteries."

    The company has appointed Carl J. St. Bernard as Jupiter Endovascular's Chief Executive Officer. St. Bernard, an industry veteran with a wealth of medical technology leadership experience, joins Jupiter from Alta Biomaterials, where he held the role of President and CEO. He has over 30 years of experience in the life sciences arena and has held senior executive positions at CeloNova BioSciences, Tryton Medical, Johnson & Johnson Vision, LifeCell, Cordis, and GE Healthcare. He is also an AdvaMed board director.

    "I am very excited to join the Jupiter Endovascular team. The Endoportal ControlTM technology, which leverages Jupiter's unique and exclusive intellectual property to create a catheter-based device that flexibly navigates through a patient's vasculature before fixing into a stable position, is designed to give interventionalists the confidence and support they need to deliver a prescribed cardiovascular therapy. This represents a generational advance in technology with the potential to revolutionize the treatment of millions of patients worldwide," said St. Bernard. "We are thrilled to partner with Sonder Capital and our other highly valued investors as we bring this innovation to the clinic and create the foundation for our entry into the Pulmonary Embolism market and future clinical areas where we see a compelling opportunity for Endoportal ControlTM to improve the lives and well-being of patients."

    "We are excited to welcome Carl St. Bernard as the CEO of Jupiter Endovascular," said Jay Watkins, Co-Chair and Partner at Sonder Capital. "Carl brings a wealth of experience and a proven track record of success in bringing novel technologies and therapies to market. His vision and leadership will be instrumental as the Jupiter team enters this next clinical phase. We are confident that, under Carl's guidance, Jupiter Endovascular will address a significant clinical need that has remained unmet for decades."

    About Jupiter Endovascular

    Jupiter Endovascular is a medical technology startup developing the endoportal procedure, a new class of endovascular procedures using Endoportal ControlTM to bring the precision and control of direct surgical access to catheter-based interventions. The procedure uses an endoportal device that navigates flexibly through the vasculature via percutaneous access. Once in position, the endoportal device can be fixed into a stable state to deliver an interventional treatment with surgical-like precision and control from an endovascular access point. To learn more about Jupiter Endovascular, visit www.jupiterendo.com.

    About Sonder Capital

    Sonder's team of veteran investors, innovators, founder-operators, and company builders is known not only for their individual achievements, but also for their collective success in creating, funding, and leading private and public companies that have transformed healthcare for millions of patients globally — including Intuitive Surgical (NASDAQ:ISRG), Procept Biorobotics (NASDAQ:PRCT), Shockwave Medical, Auris Health, and Reflexion Medical, among others. Sonder's extensive network of limited partners is global and includes industry leaders, high-net-worth individuals, and leading family offices focused on investing in game-changing healthcare technologies. Sonder Capital was co-founded in 2019 by healthcare luminaries Jay Watkins and Fred Moll, M.D.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240815995561/en/

    Get the next $ISRG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ISRG
    $PRCT

    CompanyDatePrice TargetRatingAnalyst
    PROCEPT BioRobotics Corporation
    $PRCT
    12/2/2024$105.00Overweight
    Morgan Stanley
    Intuitive Surgical Inc.
    $ISRG
    12/2/2024$522.00 → $650.00Equal-Weight → Overweight
    Morgan Stanley
    PROCEPT BioRobotics Corporation
    $PRCT
    11/14/2024$95.00Hold
    Jefferies
    Intuitive Surgical Inc.
    $ISRG
    8/2/2024$380.00 → $510.00Neutral → Buy
    Redburn Atlantic
    Intuitive Surgical Inc.
    $ISRG
    7/10/2024$462.00 → $512.00Buy
    Citigroup
    Intuitive Surgical Inc.
    $ISRG
    5/30/2024$500.00Buy
    Goldman
    Intuitive Surgical Inc.
    $ISRG
    11/17/2023$318.00Buy
    HSBC Securities
    PROCEPT BioRobotics Corporation
    $PRCT
    8/11/2023$42.00Overweight
    Piper Sandler
    More analyst ratings

    $ISRG
    $PRCT
    Financials

    Live finance-specific insights

    See more
    • PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

      SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2025. Recent Highlights Total revenue of $69.2 million for the first quarter of 2025, an increase of 55% compared to the prior year period in 2024U.S. handpiece and consumables revenue of 38.0 million for the first quarter of 2025, an increase of 61% compared to the prior year period in 2024Sold 43 new robotic sy

      4/24/25 7:00:00 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • Intuitive Announces First Quarter Earnings

      SUNNYVALE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Intuitive (the "Company") (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended March 31, 2025. Q1 Highlights Worldwide da Vinci procedures grew approximately 17% compared with the first quarter of 2024.The Company placed 367 da Vinci surgical systems, compared with 313 in the first quarter of 2024. The first quarter 2025 da Vinci surgical system placements included 147 da Vinci 5 systems, compared with 8 in the first quarter of 2024.The Company grew its da Vinci surgical system installed base to 10,189 systems as of Mar

      4/22/25 4:05:00 PM ET
      $ISRG
      Industrial Specialties
      Health Care
    • PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting in Las Vegas, Nevada

      SAN JOSE, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today it will host an in-person investor event on Friday, April 25, 2025, at the Venetian Hotel in Las Vegas at the American Urological Association Annual Meeting from 8:00am to 9:30am Pacific Time. Members of PROCEPT BioRobotics' management team presenting include: Reza Zadno – Chief Executive OfficerKevin Waters – Chief Financial OfficerSham Shiblaq – Chief Commercial OfficerBarry Templin – Chief Technology Officer Clinical perspectives will also be

      3/14/25 8:00:00 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care

    $ISRG
    $PRCT
    SEC Filings

    See more
    • Intuitive Surgical Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - INTUITIVE SURGICAL INC (0001035267) (Filer)

      5/5/25 9:00:20 AM ET
      $ISRG
      Industrial Specialties
      Health Care
    • SEC Form 10-Q filed by PROCEPT BioRobotics Corporation

      10-Q - PROCEPT BioRobotics Corp (0001588978) (Filer)

      5/2/25 4:51:16 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by PROCEPT BioRobotics Corporation

      DEFA14A - PROCEPT BioRobotics Corp (0001588978) (Filer)

      4/25/25 4:28:36 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care

    $ISRG
    $PRCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Samath Jamie exercised 915 shares at a strike of $259.91 and sold $483,074 worth of shares (915 units at $527.95) (SEC Form 4)

      4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)

      5/5/25 4:43:58 PM ET
      $ISRG
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Director Reed Monica P

      4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)

      5/1/25 9:19:26 PM ET
      $ISRG
      Industrial Specialties
      Health Care
    • Director Nachtsheim Jami K exercised 2,400 shares at a strike of $90.49 and sold $1,248,000 worth of shares (2,400 units at $520.00) (SEC Form 4)

      4 - INTUITIVE SURGICAL INC (0001035267) (Issuer)

      5/1/25 9:12:35 PM ET
      $ISRG
      Industrial Specialties
      Health Care

    $ISRG
    $PRCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

      SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

      11/14/24 1:28:32 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

      SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

      11/12/24 5:01:10 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

      SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

      11/4/24 1:31:19 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care

    $ISRG
    $PRCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley initiated coverage on PROCEPT BioRobotics with a new price target

      Morgan Stanley initiated coverage of PROCEPT BioRobotics with a rating of Overweight and set a new price target of $105.00

      12/2/24 7:01:00 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • Intuitive Surgical upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Intuitive Surgical from Equal-Weight to Overweight and set a new price target of $650.00 from $522.00 previously

      12/2/24 6:57:53 AM ET
      $ISRG
      Industrial Specialties
      Health Care
    • Jefferies initiated coverage on PROCEPT BioRobotics with a new price target

      Jefferies initiated coverage of PROCEPT BioRobotics with a rating of Hold and set a new price target of $95.00

      11/14/24 8:28:45 AM ET
      $PRCT
      Medical/Dental Instruments
      Health Care

    $ISRG
    $PRCT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Intuitive Announces FDA Clearance of da Vinci Single Port for Transanal Local Excision/Resection

      SUNNYVALE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced today that the U.S. Food and Drug Administration (FDA) cleared the da Vinci Single Port (SP) surgical system for transanal local excision/resection, a form of minimally invasive surgery performed through a natural orifice to avoid abdominal surgical incisions for select procedures. This clearance extends the da Vinci SP's capabilities in colorectal surgery, building upon procedures previously cleared by the FDA in November 2024, which include transabdominal procedures - low anterior resection, total mesorec

      5/1/25 9:15:00 AM ET
      $ISRG
      Industrial Specialties
      Health Care
    • PROCEPT BioRobotics® to Attend Four Upcoming Investor Conferences in May & June

      SAN JOSE, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that members of management will present at four upcoming investor conferences in May and June. 2025 Bank of America Health Care Conference Location – Las Vegas, NVFireside Chat – Wednesday, May 14 at 3pm PT / 6pm ET 45th Annual William Blair Growth Stock Conference Location – Chicago, ILPresentation – Wednesday, June 4 at 10am CT / 11am ET 2025 Jefferies Global Healthcare Conference Location – New York City, NYFireside Chat – Thursday, June 5 at 8:45m ET

      4/29/25 4:03:00 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care
    • PROCEPT BioRobotics' Aquablation Therapy Spotlighted at 2025 AUA Annual Meeting Along with Expert-Led Workshops

      Presentations underscore long-term clinical outcomes, safety and durability in BPH treatment Attendees invited to experience hands-on HYDROS Robotic System demonstrations SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT)  ("PROCEPT"), a surgical robotics company whose mission is to revolutionize BPH treatment globally, today announced an extensive lineup of scientific presentations and interactive workshops at the 2025 American Urological Association (AUA) Annual Meeting, taking place April 26–29 in Las Vegas, Nevada. Clinical data presentations will highlight long-term outcomes, safety and durability of Aquablation® therapy for BPH. Th

      4/24/25 4:03:00 PM ET
      $PRCT
      Medical/Dental Instruments
      Health Care

    $ISRG
    $PRCT
    Leadership Updates

    Live Leadership Updates

    See more
    • DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P

      3/7/25 6:19:00 PM ET
      $ALK
      $AMBC
      $ATI
      $BBWI
      Air Freight/Delivery Services
      Consumer Discretionary
      Property-Casualty Insurers
      Finance
    • Astera Labs Appoints Dr. Craig Barratt to Board of Directors

      SANTA CLARA, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Astera Labs, Inc. (NASDAQ:ALAB), a global leader in semiconductor-based connectivity solutions for AI and cloud infrastructure, today announced the appointment of Dr. Craig Barratt to its Board of Directors. Dr. Barratt is a seasoned technology industry veteran with decades of experience as an impactful leader and board member at networking, semiconductor, and medical device companies. "Craig's proven track record of scaling high-growth technology companies and driving breakthrough innovations at industry leaders like Atheros, Google, and Qualcomm makes him an invaluable addition to Astera Labs' Board of Directors," said Jitendra Moh

      3/3/25 4:05:00 PM ET
      $ALAB
      $ISRG
      Semiconductors
      Technology
      Industrial Specialties
      Health Care
    • Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner

      SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner. Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered th

      10/28/24 7:00:00 AM ET
      $ISRG
      $PRCT
      $SNBR
      $SWAV
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
      Home Furnishings